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ABSTRACT 
 
Objectives: The clinical heterogeneity of Frontotemporal Dementia (FTD) complicates 
identification of biomarkers for clinical trials that may be sensitive during the pre-diagnostic 
stage. It is not known whether cognitive or behavioural changes during the preclinical period are 
predictive of genetic status or conversion to clinical FTD. The first objective was to evaluate the 
most frequent initial symptoms in patients with genetic FTD. The second objective was to 
evaluate whether preclinical mutation carriers demonstrate unique FTD-related symptoms 
relative to familial mutation non-carriers. 
 
Methods: The current study used data from the Genetic Frontotemporal Dementia Initiative 
(GENFI) multicentre cohort study collected between 2012-18. Participants included symptomatic 
carriers (N=185) of a pathogenic mutation in C9orf72, GRN or MAPT and their first-degree 
biological family members (N=588). Symptom endorsement was documented using informant 
and clinician-rated scales.  
 
Results: The most frequently endorsed initial symptoms amongst symptomatic patients were 
apathy (23%), disinhibition (18%), memory impairments (12%), decreased fluency (8%), and 
impaired articulation (5%). Predominant first symptoms were usually discordant between family 
members. Relative to biologically related non-carriers, preclinical MAPT carriers endorsed worse 
mood and sleep symptoms, and C9orf72 carriers endorsed marginally greater abnormal 
behaviours. Preclinical GRN carriers endorsed less mood symptoms compared to non-carriers, 
and worse everyday skills. 
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Conclusion: Preclinical mutation carriers exhibited neuropsychiatric symptoms compared to 
non-carriers that may be considered as future clinical trial outcomes. Given the heterogeneity in 
symptoms, the detection of clinical transition to symptomatic FTD may be best captured by 
composite indices integrating the most common initial symptoms for each genetic group.  
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INTRODUCTION 
 
Frontotemporal dementia (FTD) is a neurodegenerative disorder with approximately 30% of 
patients showing a strong family history, with mutations in the chromosome 9 open reading 
frame 72 (C9orf72), progranulin (GRN) or microtubule-associated protein tau (MAPT) genes 
each accounting for 5-10% of patients with FTD [1]. While therapies targeting the underlying 
pathology are in development [2], currently, no treatments are available to prevent or alter the 
course of disease progression. 
 
Even during the early stages of disease, symptoms of FTD are quite impairing [3]; thus, 
treatments will likely need to intervene during the preclinical stage, before a patient meets the 
current international consensus criteria [4,5]. Consequently, there is a growing interest in 
identifying biomarkers and clinical endpoints that can best inform when to administer these 
interventions and how to track treatment efficacy. A major challenge in designing clinical trials 
and the designation of clinical endpoints is the heterogeneity of genetic FTD at the phenotypic 
[6], and pathological levels [7,8]. For instance, clinical symptoms in genetic FTD range from 
language disturbances [5] to behavioural and neuropsychiatric features [4], which occur at 
various frequencies and ages even within families, and have different neuroanatomic associations 
[9,10]. Furthermore, at present, it is not yet known whether or when symptoms associated with 
genetic FTD may occur during the prodromal period, and whether such symptoms may be 
specific to the later development of clinical FTD.  
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To inform clinical endpoint selection for future clinical trials in at-risk cohorts, the first objective 
of the current study was to evaluate the most frequent initial symptoms in patients with 
symptomatic genetic FTD due to C9orf72, GRN or MAPT mutations. The second objective was 
to evaluate whether preclinical mutation carriers demonstrate greater or different symptoms 
relative to biologically related non-carriers during the preclinical period.  
 
METHOD 
 
Participants 
The current study used data from the Genetic Frontotemporal Dementia Initiative (GENFI) 
multicentre cohort study, which consists of research centres across Europe and Canada 
(http://genfi.org.uk/). This dataset is comprised of (1) known symptomatic carriers of a 
pathogenic mutation in the GRN or MAPT genes or with a pathogenic expansion in the C9orf72 
gene (greater than 30 repeats) with clinical diagnoses based on the international consensus 
diagnostic criteria [4,5], and (2) first-degree biological family members of a known GRN, MAPT 
or C9orf72 mutation carrier who are at-risk for developing FTD and were not yet demonstrating 
evidence of progressive cognitive or behavioral symptoms (including both preclinical carriers 
and non-carriers). All eligible and interested participants were enrolled in the study. Importantly, 
the majority of at-risk family members in the GENFI study, and the local GENFI research teams, 
were not aware of their genetic status at the time of the assessments. After their baseline visit, 
participants were followed for up to five annual visits. All participants had an identified 
informant who completed clinical scales (see below). Participants with completed study 
measures were included in the analysis; information on other demographic variables was 
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complete for all participants in the study. The data was part of the GENFI data freeze 4 collected 
at 22 GENFI sites (2012-2018). Local ethics committees at each site approved the study and all 
participants provided written informed consent at enrollment. 
 
Study Measures 
GENFI Symptom List: The initial 37-symptom list was designed to include a variety of FTD-
related symptoms based on standardized rating scales (e-method 1.0, Table e-1, e-2 and e-results 
2). Informants of symptomatic patients (typically a spouse or sibling) described the initial 
symptom and trained research coordinators selected the corresponding symptom from the list. 
For at-risk family members, clinicians completed the GENFI symptom list with the at-risk family 
member and their study informant, and evaluated the presence of each symptom using a 5-point 
Likert scale (0=absent, 0.5= questionable/very mild, 1=mild, 2=moderate, 3=severe). Symptom 
ratings of questionable/very mild, mild, moderate, severe were coded as symptom endorsement 
and absent coded as symptom absent. 
 
Cambridge Behavioural Inventory Questionnaire-Revised (CBI-R): Informants of at-risk family 
members completed the CBI-R [11]. This questionnaire was used to evaluate the at-risk groups’ 
current symptoms within the past 4 weeks. Each question is evaluated on a 5-point scale, where 
higher scores indicate greater symptom endorsement and severity. Symptom domains included 
memory and orientation, everyday skills, self-care, abnormal behaviour, mood, beliefs, eating 
habits, sleep, stereotypic and motor behaviours and motivation. Each domain includes 2 to 8 sub-
items.  
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Years from expected onset was used to determine whether participants who were closer to the 
age of anticipated clinical onset endorsed greater symptoms. Years from expected onset (YEO) 
was calculated by subtracting the mean age of clinical onset within the family from the 
participant’s current age [10,12]. Negative values denote that the participant is at an age prior to 
expected clinical onset; positive values indicate that the participant is at an age after expected 
clinical onset.  
 
Statistical Analysis 
GENFI Symptom List: Descriptive statistics were used to illustrate the most frequent symptoms 
endorsed at participants’ initial visits. Differences amongst the three genetic groups in the 
frequency of the most prevalent sub-symptoms were examined using Chi-squared test or Fisher’s 
exact test for the symptomatic patients and at-risk individuals, and separately comparing 
preclinical mutation carriers and non-carriers for each gene mutation. Mixed models were not 
used to account for potential clustering effects of family membership and site, due to the low 
symptom endorsement (creating small samples) by patients and at-risk family members.  
 
For symptomatic and at-risk family members, a composite index was created for each gene based 
on three most frequently endorsed initial symptoms for each of the symptomatic genetic groups 
(C9orf72 & MAPT: disinhibition, apathy, memory; GRN: apathy, articulation, fluency). For each 
composite, participants attained a score of 1 if they endorsed at least one symptom within each 
composite (0=no symptoms endorsed, 1= at least one symptom endorsed). Note only the 
predominant initial symptom was recorded in the GENFI intake for affected participants. To 
evaluate the effectiveness of this composite to differentiate between mutation carriers and non-
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carries, sensitivity and specificity values were computed 
(https://www.medcalc.org/calc/diagnostic_test.php).  
 
To evaluate changes in symptom endorsement over time in at-risk family members who had at 
least one follow-up visit, a difference score was calculated by subtracting symptom endorsement 
at the final visit from symptom endorsement at the first visit (0=not endorsed, 1=symptom 
endorsed). This resulted in three categories for each symptom: decrease in symptom 
endorsement over time (score of -1), no change in symptom endorsement over time (score of 0), 
increase in symptom endorsement over time (score of 1). Calculating change scores enabled all 
participants to be included in the analysis, regardless of the number of follow-up visits. Chi-
squared tests/Fisher’s Exact tests were completed to assess group differences.  
 
To evaluate whether the initial symptoms were similar amongst patients from the same family, a 
congruency score was calculated as the number of pairwise comparisons in which family 
members shared an initial symptom, divided by the total number of possible pairwise 
comparisons. A congruency score was also calculated to evaluate the congruency of initial 
predominant symptoms for specific GRN and MAPT mutations. 
 
Cambridge Behavioural Inventory Questionnaire-Revised: A generalized linear mixed model 
with a Laplace likelihood approximation function was used to examine differences in the total 
CBI-R scores between preclinical mutation carriers vs. non-mutation carriers at the initial 
GENFI visit as a function of years from expected clinical onset. This analysis accounted for 
potential clustering effects based on family membership. Plots of the CBI-R total scores 
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suggested a Poisson distribution; however, due to overdispersion as indicated through the 
Pearson Chi-Square/DF, a negative binomial distribution with a log link function was used. No 
participant had studentized residuals greater than +/- 3, and thus all data points were included in 
the analysis. Predictor variables included random effects [family membership] and fixed effects 
[genetic status (preclinical vs. non-carriers), years from expected onset, and an interaction 
between genetic status and years from expected onset]. Examination of the residuals suggested 
the use of weights to account for the within-family correlation in the model. Given the variability 
in contribution of family membership to predicting age of onset by mutation group [10], a 
confirmatory analysis was conducted substituting years from expected onset with the 
participant’s age. Of note, as age was highly correlated with years from expected onset (r=0.84, 
p<0.001), participant’s age could not be included in the model due to multicollinearity. However, 
when age was substituted for estimated years from expected onset, the pattern of results was 
similar (Table e-3).  
 
 
Change scores (symptom score at final visit – score at first visit)/ time interval) were calculated 
to compare longitudinal data. Participants with studentized residuals greater than +/- 3 were 
removed (Table e-4), and a linear mixed model was used (see e-methods 3.0 on the description 
of the model formation). Predictor variables included random effects [family membership] and 
fixed effects [genetic status (preclinical vs. non-carriers), years from expected onset or 
participant’s age, CBI total score at baseline, and an interaction between genetic status and years 
from expected onset]. A confirmatory analysis was run substituting participant’s age at baseline 
for the years from expected onset (Table e-3). As differences between the preclinical and non-
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carriers in the total CBI scores may be obscured by opposed group differences in the sub-scale 
scores, we also examined group differences at baseline and longitudinally for each of the sub-
scales by using the model developed for the total score. For these models, the same parameters 
were used with one exception: the sub-scale score at baseline was used as a fixed effect instead 
of the CBI total score at baseline. For both the baseline and change score analysis, the potential 
influence of specific FTD-causing mutations was examined by assessing the impact of genetic 
mutation type as the grouping variable (C9orF72, GRN, MAPT, mutation non-carriers), and post-
hoc comparisons were conducted between each genetic group and non-carriers. For brevity, the 
results from the models with the genetic mutation group are reported in the manuscript.  
 
RESULTS 
 
Participants 
185 patients diagnosed with FTD (C9orf72 n=87, GRN n=65, MAPT n=33) were included in the 
analysis. Additionally, 637 at-risk family members (317 preclinical mutation carriers, 320 
mutation non-carriers) and 588 at risk individuals (294 preclinical carriers, 294 non-carriers) 
completed the GENFI symptom list and CBI-R scales, respectively (Table 1).   
 
Predominant Initial Symptoms in Symptomatic Patients 
Across the entire cohort the most frequently endorsed initial symptoms were apathy (23%), 
disinhibition (18%), memory impairments (12%) decreased fluency (8%) and impaired 
articulation (5%; Figure 1, Table e-5). When the most frequent initial symptoms were compared 
amongst the mutation groups, patients with MAPT mutations presented with disinhibition more 
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frequently relative to C9orf72 and GRN carriers, and displayed memory impairments more 
frequently than GRN carriers. GRN carriers exhibited impaired articulation and decreased 
fluency more often than C9orf72 and MAPT carriers. No group differences were observed for 
apathy.  
 
Symptom Congruency 
14 families had at least two related patients in the study cohort; amongst these families, the 
average percentage congruency for first symptom similarity was 19% (Table e-6). Five families 
with a MAPT mutation and 7 families with a GRN mutation had at least two related symptom 
patients in the study cohort and the specific genotype was known. Of the specific genotypes, the 
average congruency score was 33% for MAPT and 20% for GRN mutations (Table e-7). 
EARLY SYMPTOMS AND FRONTOTEMPORAL DEMENTIA                                                    Tavares et al, 15 
 
 
 
Table 1: Demographics table for symptomatic and at-risk family members 
 Symptomatic Patients At-risk Family Members 
 Total C9orf72 GRN MAPT Contrasts Preclinical
&
 Non-carrier
&
 Contrasts
&
 Preclinical
^
 Non-carrier
^
 Contrasts
^
 
N 185 87 65 33  317 320  294 294  
Handedness     p=0.02
*#   p=0.16*#   p=0.14*# 
Right 174 80 65 29  282 298  275 262  
Left 9 5 0 4  31 20  17 28  
Ambidextrous 2 2 0 0  4 2  2 4  
Sex     X
2=6.2, 
p=0.045 
  X2=0.90, 
p=0.34 
  X2=0.86, 
p=0.35 
Male 108 57 30 21  123 136  112 123  
Female 77 30 35 12  194 184  182 171  
Genotype        X
2=0.21, 
p=0.90 
  X2=0.58, 
p=0.75 
C9orf72      117 115  104 103  
GRN      144 144  138 132  
MAPT      56 61  52 59  
Maximum 
number of visits 
           
1      121 118  124 122  
2      80 98  80 95  
3      72 58  60 38  
4      30 27  22 23  
5      10 15  7 16  
6      4 4  1 0  
Diagnosis            
bvFTD  62 33 31        
PPA 
 
 4 28 0        
FTD-ALS  9 0 0        
ALS  6 0 0        
PSP  1 0 0        
CBS  0 2 1        
AD  0 1 0        
Dementia- NOS  3 1 1        
Other  2 0 0        
Time interval for 
change score (SD) 
     2.6 (1.4) [n=196] 2.5 (1.5) 
[n=202] 
t(394.7) = -0.6, 
p=0.54 
2.5 (1.3) [n=170] 2.4 (1.5) [n=172] t(340)= -0.7, 
p=0.49 
Age (SD) 62.3 
(8.5) 
63.7 (8.3) 63.5 
(6.9) 
56.2 (9.5) F(2,184)=11.5, 
p<0.001# 
C9> MAPT 
GRN > MAPT 
44.0 (11.8) 46.3 (14.0) t(619)=2.3, 
p=0.03 
44.0 (11.9) 46.7 (14.1) t(570.1)=2.6, 
p=0.01 
Age at onset (SD) 58.1 
(8.8) 
58.8 (9.0) 60.6 
(7.2) 
51.1 (7.7) F(2,184)=11.5, 
p<0.001# 
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C9>MAPT 
GRN >MAPT 
Education, Yrs, 
(SD) 
12.2 
(4.0) 
12.6 (4.0) 11.2 
(4.0) 
13.2 (3.6) F(2,184)=3.5, 
p=0.03# 
MAPT> GRN 
(p=0.065) 
14.3 (3.3) 13.9 (3.6) t(635)= -1.5, 
p=0.13 
14.3 (3.3) 13.9 (3.6) t(586)= -1.58, 
p=0.1 
Years from 
expected symptom 
onset (SD)
**
 
     -14.4 (11.8) -13.2 (14.1) t(618.5) = 1.17, 
p=0.24 
-14.5 (12.0) -12.9 (14.2) t(569.3)= 
1.51, p=0.13 
 Chi-squared, Fisher’s Exact tests (if expected cell count was less than 5), independent sample t-tests or one-way analysis of variance were used to discern group 
differences for relevant variables 
 # Bonferroni correction applied 
 &At-risk participants from 248 families. Participants completed the GENFI symptom list  
 ^At-risk participants from 228 families. Participants completed the CBI questionnaire 
 *#Fisher’s Exact Test was used 
 **Years from expected onset was calculated by subtracting the participant’s age at the time of participation from the mean age of symptom onset within the family 
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Symptom Endorsement in at-risk Family Members (GENFI symptom list) 
There were no significant differences between at-risk individuals (preclinical C9orf72, GRN, 
MAPT vs. non-carriers) or between preclinical genetic groups in the proportion of participants 
who endorsed the initial symptoms most commonly reported in affected patients (i.e. apathy, 
disinhibition, decreased fluency, impaired articulation and memory impairments) (Figures 2 & 
Table e-5, e-8). Overall, at-risk genetic groups (preclinical C9orf72, GRN, MAPT vs. non-
carriers) showed a similar pattern of symptom endorsement over time, with a very low 
proportion of participants reporting changes in the most common initial symptoms (Table e-9).  
 
 
Composite Scores 
The sensitivity and specificity values indicate the composite indices differentiate between 
symptomatic FTD and non-mutation carriers for each of the gene groups with sensitivities from 
94% to 97% and specificities of 80%. For at-risk family members, the composite indices showed 
low sensitivity (8-33%), with medium specificity (76-91%) to differentiate between preclinical 
mutation carriers from non-carriers beginning from -5, -2 and 0 years to expected age of onset 
(Table e-10, e-11).  
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Symptom Endorsement & Severity in at-risk Family Members (CBI-R questionnaire) 
CBI-R scores at baseline: As participants approached the anticipated time of onset there was a 
significant increase in the reported total symptom score, memory and orientation, sleep, 
motivation, eating habits, and stereotypic and motor behaviours scores. When adjusting for 
expected years to onset and relative to non-carriers, post-hoc contrasts showed that MAPT 
carriers experienced greater mood, sleep, and motivation symptoms; C9orf72 carriers endorsed 
greater abnormal behaviour and stereotypic & motor symptoms; and GRN carriers had lower 
mood scores (Table 2; Figure 3).  
 
Longitudinal CBI scores: Improved symptoms over time (negative change scores) were 
associated with greater symptom scores at baseline when adjusted for expected years to onset 
and carrier status across all participants. There were also significant associations between 
expected years to onset and memory and orientation scores, stereotypic and motor behaviours, 
but also for eating habits (Table 2). Within the sub-scales, GRN and C9orf72 preclinical carriers 
demonstrated worse everyday skills over time relative to mutation non-carriers, but only the 
GRN carriers’ scores met statistical significance (Figure 4).  
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Table 2: CBI total and sub-scale scores at baseline and over time for at-risk family members by genetic group (no outliers 
included) 
 Baseline
#
 Change Score 
 N Estimate (95% CI) p-value N Estimate (95% CI) p-value 
Total Score  588   336   
C9orf72  104 1.34 (0.78, 2.31) 0.29  0.28 (-1.42, 1.97) 0.75 
GRN  138 0.95 (0.52, 1.73) 0.86  0.38 (-0.8, 1.56) 0.53 
MAPT  52 1.96 (0.88, 4.38) 0.1  0.39 (-1.37, 2.15) 0.66 
YEO  1.02 (1, 1.03) 0.02  0.03 (-0.01, 0.07) 0.11 
Baseline score  - -  -0.15 (-0.21, -0.1) <.0001 
C9orf72*YEO  1 (0.98, 1.03) 0.8  0.01 (-0.08, 0.11) 0.78 
GRN*YEO  1 (0.97, 1.03) 0.87  -0.02 (-0.08, 0.05) 0.63 
MAPT*YEO  1 (0.96, 1.05) 0.85  -0.01 (-0.12, 0.1) 0.86 
Memory and Orientation  588   334   
C9orf72  104 0.88 (0.51, 1.52) 0.65 49 -0.02 (-0.41, 0.37) 0.92 
GRN  138 1.03 (0.56, 1.89) 0.92 85 -0.03 (-0.3, 0.25) 0.85 
MAPT  52 0.89 (0.39, 2.03) 0.78 33 -0.01 (-0.42, 0.41) 0.98 
YEO  1.03 (1.01, 1.04) 0.001  0.01 (0.002, 0.02) 0.02 
Baseline score  - -  -0.18 (-0.23, -0.13) <.0001 
C9orf72*YEO  0.98 (0.96, 1.01) 0.29  -0.003 (-0.02, 0.02) 0.74 
GRN*YEO  1.01 (0.98, 1.04) 0.47  -0.002 (-0.02, 0.01) 0.78 
MAPT*YEO  0.99 (0.95, 1.03) 0.59  0.0003 (-0.02, 0.03) 0.98 
Everyday Skills 588   335   
C9orf72  104 0.77 (0.09, 6.56) 0.81 50 0.07 (-0.01, 0.14) 0.09 
GRN  138 0.71 (0.1, 4.92) 0.72 85 0.11 (0.05, 0.16) 0.0001 
MAPT  52 1.08 (0.05, 22.27) 0.96 32 0.03 (-0.06, 0.11) 0.53 
YEO  1.03 (0.97, 1.09) 0.34  0.001 (0, 0) 0.57 
Baseline score  - -  -0.5 (-0.55, -0.45) <.0001 
C9orf72*YEO  1 (0.89, 1.13) 0.96  0.003 (0, 0.01) 0.21 
GRN*YEO  1.05 (0.93, 1.2) 0.42  0.003 (0, 0.01) 0.07 
MAPT*YEO  0.96 (0.82, 1.11) 0.57  0.0002 (0, 0.01) 0.95 
Abnormal Behaviour 588   334   
C9orf72  104 2.16 (1.09, 4.26) 0.03 48 -0.02 (-0.3, 0.25) 0.86 
GRN  138 0.83 (0.36, 1.91) 0.67 86 -0.03 (-0.22, 0.15) 0.73 
MAPT  52 2.07 (0.8, 5.38) 0.14 33 -0.02 (-0.3, 0.26) 0.89 
YEO  1 (0.98, 1.02) 0.9  0.004 (0, 0.01) 0.19 
Baseline score  - -  -0.23 (-0.28, -0.18) <.0001 
C9orf72*YEO  1.02 (0.98, 1.06) 0.37  -0.006 (-0.02, 0.01) 0.47 
GRN*YEO  1 (0.96, 1.04) 0.99  -0.007 (-0.02, 0) 0.23 
MAPT*YEO  0.99 (0.95, 1.04) 0.77  -0.0033 (-0.02, 0.01) 0.71 
Mood 587   334   
C9orf72  104 1.22 (0.7, 2.12) 0.49 49 -0.07 (-0.47, 0.34) 0.75 
GRN  137 0.46 (0.23, 0.93) 0.03 84 0.18 (-0.11, 0.47) 0.2 
MAPT  52 2.75 (1.29, 5.89) 0.01 33 0.38 (-0.05, 0.81) 0.08 
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YEO  1.01 (0.99, 1.03) 0.26  -0.002 (-0.01, 0.01) 0.7 
Baseline score  - -  -0.23 (-0.28, -0.18) <.0001 
C9orf72*YEO  1 (0.97, 1.03) 0.80  -0.018 (-0.04, 0) 0.11 
GRN*YEO  0.97 (0.94, 1) 0.05  -0.003 (-0.02, 0.01) 0.73 
MAPT*YEO  1.01 (0.97, 1.05) 0.58  0.0031 (-0.02, 0.03) 0.81 
Beliefs    340   
C9orf72     49 -0.004 (-0.02, 0.01) 0.56 
GRN     86 -0.01 (-0.02, 0.0014) 0.097 
MAPT     33 -0.01 (-0.02, 0.01) 0.46 
YEO     0.00007 (-0.0002, 0.0004) 0.62 
Baseline score     -0.38 (-0.41, -0.34) <.0001 
C9orf72*YEO     -0.00017 (-0.0009, 0.0005) 0.64 
GRN*YEO     -0.00017 (-0.0007, 0.0004) 0.52 
MAPT*YEO     -0.0001 (-0.0009, 0.0007) 0.86 
Eating habits 588   335   
C9orf72  104 0.61 (0.16, 2.32) 0.46 49 -0.02 (-0.2, 0.16) 0.83 
GRN  138 1.57 (0.46, 5.39) 0.47 86 0 (-0.13, 0.1247) 0.99 
MAPT  52 0.68 (0.1, 4.82) 0.70 32 0.1 (-0.09, 0.29) 0.29 
YEO  1.05 (1.01, 1.09) 0.01  0.0041 (0.0001, 0.008) 0.04 
Baseline score  - -  -0.35 (-0.39, -0.31) <.0001 
C9orf72*YEO  0.96 (0.89, 1.03) 0.25  -0.006 (-0.02, 0.005) 0.28 
GRN*YEO  1 (0.94, 1.07) 0.91  -0.00002 (-0.007, 0.007) 0.996 
MAPT*YEO  0.95 (0.87, 1.05) 0.35  0.003 (-0.008, 0.01) 0.6 
Sleep 588   334   
C9orf72  104 1.4 (0.75, 2.64) 0.29 49 -0.13 (-0.39, 0.13) 0.33 
GRN  138 1.16 (0.56, 2.39) 0.68 86 0.05 (-0.14, 0.23) 0.62 
MAPT  52 3.37 (1.46, 7.74) 0.004 32 0.02 (-0.26, 0.3) 0.89 
YEO  1.03 (1.01, 1.05) 0.01  -0.0009 (-0.007, 0.005) 0.76 
Baseline score  - -  -0.28 (-0.33, -0.22) <.0001 
C9orf72*YEO  1.01 (0.97, 1.05) 0.56  -0.008 (-0.02, 0.006) 0.25 
GRN*YEO  1 (0.96, 1.04) 0.86  0.003 (-0.008, 0.01) 0.63 
MAPT*YEO  1.03 (0.98, 1.08) 0.26  -0.005 (-0.02, 0.01) 0.54 
Stereotypic and motor 
behaviours 
588   335   
C9orf72  104 2.15 (1.05, 4.39) 0.04& 49 -0.12 (-0.42, 0.18) 0.44 
GRN 138 1.07 (0.46, 2.52) 0.87 86 0.08 (-0.13, 0.28) 0.47 
MAPT 52 1 (0.31, 3.23) 0.999 32 0.002 (-0.31, 0.32) 0.99 
YEO  1.02 (1, 1.05) 0.05  0.0079 (0.001, 0.01) 0.02 
Baseline score  - -  -0.3 (-0.37, -0.24) <.0001 
C9orf72*YEO  1.03 (0.98, 1.07) 0.23  -0.01 (-0.03, 0.007) 0.23 
GRN*YEO  1 (0.96, 1.05) 0.96  0.0001 (-0.01, 0.01) 0.99 
MAPT*YEO  0.94 (0.89, 1) 0.05  0.002 (-0.02, 0.02) 0.86 
Motivation 587   330   
C9orf72  104 1.91 (0.72, 5.06) 0.19 49 0.093 (-0.19, 0.38) 0.52 
GRN  138 0.93 (0.31, 2.75) 0.9 84 0.02 (-0.19, 0.22) 0.88 
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MAPT  52 3.68 (1, 13.52) 0.05
& 31 0.0004 (-0.3, 0.3) 1 
YEO  1.05 (1.02, 1.08) 0.003  0.002 (-0.0047, 0.008) 0.62 
Baseline score  - -  -0.26 (-0.33, -0.19) <.0001 
C9orf72*YEO  0.98 (0.93, 1.04) 0.51  0.005 (-0.0109, 0.02) 0.54 
GRN*YEO  0.97 (0.92, 1.02) 0.26  0.006 (-0.0057, 0.02) 0.31 
MAPT*YEO  0.97 (0.9, 1.04) 0.41  -0.006 (-0.0247, 0.01) 0.49 
 Statistics are from the Solution for Fixed Effects Table 
 #Baseline data was modeled with a negative binomial distribution with a log link function. Estimates and confidence intervals of fixed 
effects are exponentiated (base e) and indicate the incident rates. Estimates below 1 indicate an inverse relationship between the variable 
and outcome 
 &Overall effect of genetic group was not statistically significant at p<0.05 (based on Type III Tests of Fixed Effects) 
 The model could not be run on some subscales after outliers were removed due to low symptom endorsement. At baseline, for the self-
care sub-scale, 3 participants (3 preclinical) had scores above zero after outliers were removed. At baseline, for the beliefs sub-scale, 4 
participants (1 preclinical, 2 non-carrier) had scores above zero after outliers were removed. For the change score, for the self-care scale, 1 
non-carrier endorsed a change in symptom.  
 For the main effect of genetic group and Gene*EYO interaction= reference group are the non-carriers 
 YEO= Years from estimated onset; CI=confidence interval 
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DISCUSSION 
 
As the first study to compare initial symptoms in symptomatic and at-risk patients with genetic 
FTD across the three main genetic mutations MAPT, C9orf72 and GRN, our findings 
demonstrate the overlap and differences in the presence and frequencies of specific FTD-related 
symptoms. We also report the first longitudinal differences between preclinical mutation carriers 
in comparison to familial non-carriers in the endorsement of symptoms prior to diagnosis. 
Important to the interpretation of symptom reports and design of clinical trials, we found that 
preclinical MAPT and C9orf72 mutation carriers endorsed greater symptoms at the initial 
assessment (approximately 14 years prior to anticipated age of onset), and over time GRN and 
C9orf72 mutation carries exhibited poorer everyday skills. The direct comparison of symptoms 
among mutation groups may be important in the consideration of basket-design clinical trials 
where, for example, patients with TDP-43 pathology arising from different mutations (C9orf72 
& GRN) may be grouped together. 
 
Symptomatic Period 
While apathy and disinhibition were the most frequent initial symptoms across the mutation 
groups, some gene specific patterns emerged. The relative proportion of MAPT carriers (46%) 
endorsing disinhibition as the initial complaint relative to C9orf72 carriers (15%) and GRN 
carriers (8%) is similar to group differences previously reported where 93% of MAPT carriers 
exhibited signs of disinhibition over the course of their disease relative to 63% of C9orf72 and 
56% of GRN carriers[9]. GRN carriers endorsed impaired articulation and decreased fluency 
most often, which corresponds with the language-based clinical presentation found in some 
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patients in this mutation group [9,13]. C9orf72 expansion carriers reported motor symptoms 
most often which is consistent with reports of Amyotrophic Lateral Sclerosis found only in 
C9orf72 carriers and absent in GRN and MAPT [9]. Although the symptoms discussed above are 
characteristic of the specific gene affected, it is critical to recognize that these symptoms are not 
endorsed by all the participants in each genetic group. Utilizing the top three most frequently 
endorsed symptom to create a composite index for each genetic group differentiated 
symptomatic genetic carriers from non-carriers. Future research assessing the severity of these 
frequently endorsed initial symptoms may aid in the differentiation between the genetic groups, 
and thus may be considered as an outcome measure or clinical endpoint in future clinical trials 
for early stage FTD.  
 
 
Preclinical Period  
Overall, and counter to our predictions, the rates of initial symptoms as endorsed by preclinical 
genetic mutation carriers and non-carriers were similar to the rates of initial symptoms endorsed 
by affected patients (apathy, disinhibition, memory impairments, decreased fluency and impaired 
articulation). Similarly, preclinical and non-mutation carriers did not differ in their rates of the 
most common symptoms endorsed and the composite indices did not differentiate the groups , 
further supporting and extending recent findings indicating that some behavioural and cognitive 
changes in genetic FTD are only detectable in close proximity to conversion to the clinically 
affected state. Our cohort included biologically related non-mutation carriers which enabled us to 
control for potential environmental influences that may impact symptom endorsement (e.g. 
worry about inheriting an FTD-causing mutation, stress from a family member with FTD). 
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Although biomarkers in blood and cerebrospinal fluid, grey matter atrophy, white matter 
hyperintensities and hypometabolism have been detected prior to cognitive impairments during 
the preclinical period [1], the present findings indicate that the behavioural and cognitive 
symptoms endorsed as initial symptoms by patients may not emerge until just a few years prior 
to clear disease onset. In a recent longitudinal study of 46 preclinical mutation carriers, 8 of 
which “converted” to symptomatic during follow-up, cognitive decline during the preclinical 
period was evident but were largely driven by the convertors. Additionally, differences in 
cognitive decline between converters and preclinical mutation carriers was detectable starting 
only 2 years prior to expected onset. This may suggest that cognitive performance may remain 
relatively stable during the preclinical period and cognitive decline may begin near or at 
symptom onset [14]. This finding is also consistent with a recent study that used a classification 
model on longitudinal MRI data (anatomical, diffusion tensor imaging and resting-state) and 
reported that mutation carriers who converted during follow-up had a stronger classification 
score increase over time relative to non-converting mutation carriers [15]. Overall, these results 
propose that for some domains preclinical FTD mutation carriers may remain similar to controls 
until they are close to symptom onset.  
 
For the caregiver report, relative to non-carriers, preclinical MAPT carriers endorsed poorer 
mood and sleep symptoms, and C9orf72 carriers exhibited marginally greater abnormal 
behaviours. Moreover, GRN preclinical carriers endorsed less mood symptoms relative to non-
carriers. Given the natural co-occurrence of sleep and mood alterations, it is not surprising that 
MAPT carriers experienced symptoms in both domains. In line with our current findings, 
depressive disorder not otherwise specified has been found to be more prevalent amongst MAPT 
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preclinical carriers relative to mutation non-carriers and the general population [16]. As well, 
over a 4-year follow-up, it was reported that MAPT preclinical carriers (n=15) developed more 
depressive symptoms than GRN carriers (n=31) and healthy controls (n=39) [14]. In contrast to 
the current study, other reports have documented inconsistent findings on the prevalence of 
depressive and other neuropsychiatric symptoms during the preclinical period. For example, a 
greater lifetime prevalence of major depressive disorder, generalized anxiety disorder and panic 
disorder has previously been observed in non-carriers (n=46), but not in MAPT mutation carriers 
(n=12) [16].  Furthermore, other studies have found that neuropsychiatric features may not 
emerge until symptom onset. For example, in a Dutch cohort of  approximately 80 MAPT and 
GRN mutation and non-carriers, mutation carriers who “converted” from preclinical to 
symptomatic status (3 GRN and 5 MAPT) displayed greater depressive and general 
neuropsychiatric features relative to preclinical mutation carriers and mutation non-carriers at the 
time of clinical symptom onset [17]. In our cohort of preclinical mutation carriers, as mood 
symptoms did not emerge as participants approached their expected time of disease onset, the 
endorsement of symptoms by mutation carriers’ may reflect a developmental predisposition.  
 
When symptom endorsement was examined longitudinally, preclinical GRN carriers endorsed 
worse Everyday Skills over time compared to non-mutation carriers. Relative to healthy controls 
and normative data, asymptomatic GRN carriers demonstrate poorer performance on a variety of 
cognitive domains including attention/processing speed [18], visuospatial and working memory 
[19], verbal fluency, emotion recognition [20], attention, mental flexibility and language [21]. 
With this, it is likely that the decline in Everyday skills in preclinical GRN carriers reflects subtle 
changes in a variety of cognitive domains. Therefore, as differences are evident between GRN 
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preclinical mutation carriers and non-carriers, everyday skills as measured through the CBI-R 
may potentially be used as an end point for clinical trials in GRN preclinical individuals.  
 
 
Limitations 
Potential clustering effects of family membership and testing site could not be accounted for in 
the clinician-rating scale, due to low symptom endorsement. As well, participant’s knowledge of 
their genetic status was not obtained and thus this potential effect could not be accounted for. 
Future clinical trial modeling may need to consider the participants’ knowledge of their genetic 
status when considering rates of symptom reporting [22]. Furthermore, although the different 
scales used in the current study allow for the assessment of symptom endorsement by multiple 
informants, we could not account for potential differences in reporting style based on the sex of 
the informant or the relationship of the informant to the at-risk family member. An additional 
potential limitation is the reliance on retrospective caregiver reports to acquire reports of the 
initial symptom in symptomatic mutation carriers, though the diagnosis of FTD is reliant on 
caregiver’s reports [23].  
 
 
Conclusions 
In conclusion, , we report the frequencies of the most common initial symptoms for the main 
genetic forms of FTD and suggest that given the heterogeneity between gene groups, family 
members, and even specific mutations, composite measures of these symptoms may serve as 
clinical tools for detection of early conversion to symptomatic FTD. Of interest, we did not find 
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differences between preclinical mutation carriers and non-carriers for the most common initial 
symptoms in affected patients. Future studies examining initial symptoms with additional 
longitudinal data points will aid in the understanding of the progression of these symptom from 
the preclinical, to affected diseases stages and further pinpoint the onset of initial symptoms 
heralding conversion to symptomatic FTD.  
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Figure 1 
Title: Symptom endorsement in symptomatic patients and at-risk family members 
Legend: Percentage of patients and at-risk individuals that endorsed symptoms identified as the 
most frequent symptoms in symptomatic patients. 
 
Figure 2 
Title: Baseline symptom endorsement by genotype in at-risk family members 
Legend: Percentage of preclinical and non-mutation carriers that endorse each of the sub-
symptoms identified as the most frequent symptom in symptomatic patients 
 
Figure 3 
Title: CBI-R baseline scores by years from expected onset in preclinical mutation carriers vs. non-
carriers 
Legend: CBI-R scores at baseline for (a) abnormal behaviours (b) mood and (c) sleep (d) 
stereotypic & motor (e) motivation sub-scales. Y-axis represents the scores as modeled through the 
generalized mixed models, and X-axis represents the expected years to onset.  Blue =preclinical 
C9orf72 mutation carriers, red =preclinical GRN mutation carriers, green=preclinical MAPT 
carriers, and brown =non-carriers.  
 
Figure 4 
Title: Everyday skills change score by years from expected onset in preclinical mutation carriers vs. 
non-carriers 
Legend:  CBI-R change score for everyday skills sub-scale. Y-axis represents the linear predicted 
scores as modeled by linear mixed models and X-axis represents the expected years to onset.  Blue 
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=preclinical C9orf72 mutation carriers, red =preclinical GRN mutation carriers, green=preclinical 
MAPT carriers, and brown=non-carriers.  
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examination and sample collection; Mircea Balasa , Researcher Clinical, Performing clinical examination and sample collection; 
Miren Zulaica  , Genetic Guardian, Upload of results of molecular genetic testing; Morris Freedman , Co-investigator, Participant 
recruitment; Myriam Barandiaran , Researcher Neuropsychology, Performing neuropsychological assessment; Nick Fox , Co-
investigator, Participant recruitment; Nuria Bargalló , Researcher Imaging, Analysis of imaging; Paola Caroppo , Co-investigator, 
Participant recruitment; Pedro Rosa Neto, Researcher Imaging, Analysis of imaging; Philip Van Damme  , Researcher Clinical, 
Performing clinical examination and sample collection; Pietro Tiraboschi  , Study Coordinator, Participant recruitment, coordinating 
research visits, data upload; Rachelle Shafei  , Researcher Clinical, Performing clinical examination and sample collection; Rhian 
Convery , Research Assistant, Data collection, upload and management; Ricardo Taipa  , Co-investigator, Participant recruitment; 
Rick van Minkelen  , Genetic Guardian, Upload of results of molecular genetic testing; Rita Guerreiro , Co-investigator, Genetic 
analysis of samples; Robart Bartha , Co-investigator, Analysis of imaging; Roberto Gasparotti , Researcher Imaging, Analysis of 
imaging; Ron Keren  , Co-investigator, Participant recruitment; Rosa Rademakers  , Co-investigator, Genetic analysis of samples; 
Rose Bruffaerts , Study Coordinator, Participant recruitment, coordinating research visits, data upload; Sandra Black , Co-investigator, 
Participant recruitment; Sandra Loosli , Co-investigator, Participant assessment; Sara Mitchell , Co-investigator, Participant 
recruitment; Sara Prioni  , Co-investigator, Participant assessment; Sarah Anderl-Straub, Co-investigator, Participant assessment; 
Sebastien Ourselin , Researcher Imaging, Analysis of imaging; Serge Gauthier , Co-investigator, Participant recruitment; Sergi 
Borrego-Ecija , Co-investigator, Participant assessment; Silvana Archetti , Genetic Guardian, Upload of results of molecular genetic 
testing; Simon Mead , Genetic Guardian, Upload of results of molecular genetic testing; Sónia Afonso , Co-investigator, Participant 
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assessment; Sonja Schönecker , Co-investigator, Participant assessment; Stefano Gazzina , Researcher Clinical, Performing clinical 
examination and sample collection; Thomas Cope , Co-investigator, Performing clinical examination and sample collection; Tim 
Rittman , Co-investigator, Performing clinical examination and sample collection; Tobias Hoegen , Genetic Guardian, Upload of 
results of molecular genetic testing; Toby Flanagan , Site Coordinator, Participant recruitment, coordinating research visits, data 
upload; Valentina Bessi  , Co-investigator, Participant assessment; Veronica Redaelli , Co-investigator, Analysis of imaging; Vesna 
Jelic  , Researcher Clinical, Performing clinical examination and sample collection; Yolande Pijnenburg , Researcher Clinical, 
Performing clinical examination and sample collection; Zigor Díaz , Radiographer , Carry out MRI protocol and MRI upload. 
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